Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Huimei Closes $30 Million Round for AI-based Hospital Clinical Decision Support

publication date: Aug 30, 2019

Beijing Huimei Healthcare closed a $30 million series C round funding led by Qiming Venture Partners to continue developing its AI-based Clinical Decision Support System (CDSS). CDSS offers support for medical diagnosis, combining natural language processing (NLP), deep learning and other AI-based technologies for diagnoses and clinical data management. Founded in 2015, Huimei is partnered with the US-based Mayo Clinic as a vehicle to bring medical best practices to China. Hillhouse and Mayo provided initial funding for the joint venture company. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China